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Background/Aims: When computed tomography (CT) does 
not indicate choledocholithiasis in highly suspicious patients, 
there is no definite consensus on the subsequent modality. 
Endoscopic ultrasonography (EUS) indicates fewer procedure-
related complications than endoscopic retrograde cholangio-
pancreatography (ERCP) and has a lower cost than magnetic 
resonance cholangiopancreatography. Therefore, we aimed 
to investigate the diagnostic value of EUS in patients with 
suspected choledocholithiasis and negative CT findings. 
Methods: Between March 2008 and November 2014, we 
retrospectively evaluated 200 patients with negative CT find-
ings and high or intermediate probabilities of choledocholi-
thiasis. All patients initially underwent EUS followed by ERCP 
as a confirmatory criterion standard. The primary outcome 
in these patients was the accuracy of EUS in the detection of 
choledocholithiasis. The secondary outcome was the clinical 
prediction of common bile duct (CBD) stones in this group. 
Results: EUS indicated choledocholithiasis in 165 of the 200 
patients, and ERCP confirmed choledocholithiasis in 161 
patients (80.5%). The accuracy of EUS in the detection of 
choledocholithiasis was 94.0% (sensitivity, 97.5%; specificity, 
79.5%; positive predictive value, 95.2%; negative predictive 
value, 88.6%). A multivariate analysis demonstrated that 
choledocholithiasis was strongly predicted by EUS detection 
of choledocholithiasis, an age >55 years and a clinical diag-
nosis of cholangitis. Conclusions: An EUS-first approach is 
recommended for patients with suspected CBD stones and 
negative CT findings. (Gut Liver 2017;11:290-297)
Key Words: Choledocholithiasis; Endosonography; Cholan-
giopancreatography, endoscopic retrograde 
INTRODUCTION
Choledocholithiasis is a complication of gallstone disease that 
occurs in approximately 10% of patients with symptomatic cho-
lelithiasis.1,2 It is important to diagnose common bile duct (CBD) 
stones, because they can cause morbidity (e.g., pancreatitis and 
cholangitis) and mortality, especially if treatment is delayed.2,3 
The initial evaluation of suspected choledocholithiasis should 
include biochemical liver function tests, such as the levels of 
alkaline phosphatase (ALP), total bilirubin, alanine aminotrans-
ferase (ALT), and aspartate aminotransferase (AST), as well as 
transabdominal ultrasonography of the right upper quadrant. 
Many investigators have noted that the probability of a CBD 
stone is increased in the presence of multiple prognostic signs, 
and so the American Society for Gastrointestinal Endoscopy 
(ASGE) criteria are used to categorize patients as having a low, 
intermediate, or high probability of having choledocholithiasis, 
using their clinical and biochemical findings.4 In practice, the 
majority of patients with choledocholithiasis visit the emergen-
cy room, and so computed tomography (CT) is often the first-
line diagnostic modality, due to its convenience and its use in 
the differential diagnosis of acute abdomen (e.g., perforation).1,2 
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If choledocholithiasis is identified on CT, therapeutic endoscopic 
retrograde cholangiopancreatography (ERCP) is appropriate.1 
However, diagnostic CT often fails to detect radiolucent cho-
ledocholithiasis, such as cholesterol and small pigment stones, 
despite clinical and biochemical findings that are consistent 
with choledocholithiasis.2,3,5
Endoscopic ultrasonography (EUS) is an excellent method 
for detecting CBD stones, with a sensitivity and specificity of 
approximately 95%.3 In the last decade, numerous studies have 
demonstrated that EUS is as accurate as ERCP for detecting CBD 
stones, and that it can eliminate unnecessary ERCP procedures 
and ERCP-related complications.3,6-9 Recently, the utility of 
magnetic resonance cholangiopancreatography (MRCP) has also 
been highlighted. Five randomized, prospective, comparative 
studies were performed to compare the accuracy of choledocho-
lithiasis detection between EUS and MRCP. All studies showed 
no significant differences in sensitivity, specificity, positive and 
negative predictive values and likelihood ratio between two 
modalities.10-14 Meta-analysis of five randomized trials showed 
that the aggregated sensitivity, specificity, positive and negative 
values of EUS were 0.93, 0.96, 0.93, and 0.96, respectively; of 
MRCP they were 0.85, 0.93, 0.87, and 0.92, respectively. These 
aggregated values were not significantly different.15 Both mo-
dalities had their own merit; most of all, EUS showed greater 
convenience because, if choledocholithiasis was found, the op-
erator could perform ERCP on the spot. As well, compared with 
MRCP, EUS showed good performance for small stones and 
visualization of the biliary tree because it offered high resolu-
tion, and multiple images could be reconstructed. EUS could be 
performed on claustrophobic patients; and the cost of EUS was 
lower than that of MRCP. However, EUS accuracy was highly 
dependent upon the operator and the result could have been 
influenced by the operator’s expertise. Even a diagnostic EUS 
carried the risk of sedation and related complications such as 
perforation and bleeding. Meanwhile, the role of EUS is not 
fully established in patients with suspected choledocholithiasis 
and negative CT findings.1 Therefore, we aimed to investigate 
the usefulness of EUS in patients with an intermediate or high 
probability of suspected CBD stones and negative CT findings.
MATERIALS AND METHODS
1. Patients and study design
This retrospective study evaluated data (March 2008 to No-
vember 2014) from a prospective EUS/ERCP registry maintained 
by Inje University Sanggye Paik Hospital, Seoul, Korea and 
Myongji Hospital, Goyang, Korea. From this registry, we identi-
fied 200 patients with suspected CBD stones and negative CT 
findings. All patients underwent EUS to evaluate CBD stones 
and choledocholithiasis was confirmed by ERCP (Fig. 1). The pa-
tients’ clinical risk of choledocholithiasis was assessed using the 
ASGE guidelines, which provide a management algorithm for 
patients with symptomatic cholelithiasis according to their prob-
ability of having choledocholithiasis. Based on these criteria, 
patients were categorized as having a low (<10%), intermediate 
(10% to 50%), or high (>50%) probability of choledocholithiasis, 
using their age, liver function test results, and transabdominal 
ultrasonography findings.4 We excluded patients who had been 
diagnosed with pancreatobiliary cancer, had undergone chole-
cystectomy, or were <18 years old. Gachon University Gil Medi-
cal Center Institutional Review Board approved this retrospec-
tive study’s design (GDIRB2015-53). 
2. EUS/ERCP
Two endosonographers with at least 1,000 procedures of 
experience performed the EUS using a radial scanning echo-
endoscope (GF-UE260-AL5/UM-240; Olympus Corp., Tokyo, 
Japan). Positive identification of CBD stones was defined as a 
Fig. 1. Common bile duct stone findings on endoscopic ultrasonography (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) in 
patients with negative computed tomography findings. (A) No choledocholithiasis is apparent on computed tomography in the coronal view. (B) 
A 4-mm ovoid hyperechoic lesion with posterior acoustic shadowing (white arrow) identified in the distal common bile duct during EUS. (C) A 
4-mm cholesterol stone (white arrow) removed by ERCP.
A B C
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hyperechoic focus, with or without an acoustic shadow, which 
was observed within the CBD stone. The size of the CBD stones 
and the widths of the CBD were measured. 
ERCP was performed as a criterion standard for confirma-
tion of choledocholithiasis within 1 day after EUS using a 
TJF-240/260 duodenoscope (Olympus Corp.) by the same en-
doscopist who performed the EUS. After selective biliary can-
nulation, a cholangiogram was obtained, and sphincterotomy 
was performed when indicated. If a filling defect or stones were 
present in the CBD, bile duct sweeping and stone extraction 
were performed using a retrieval balloon and/or basket. When 
deep biliary cannulation was difficult, an aggressive cannula-
tion technique, such as infundibulotomy, needle-knife sphinc-
terotomy, or transpancreatic papillary septotomy, was used. The 
stone’s size was calculated on cholangiography when possible. 
A definitive diagnosis of choledocholithiasis was made based on 
visual assessment after stone extraction.
3. Definitions and assessment of outcomes
Biliary colic was defined as pain that was localized to the 
right upper quadrant or epigastrium. This pain usually started 
abruptly, persisted without fluctuation, and resolved gradually 
over 2 to 4 hours.16 Clinical pancreatitis was defined as new or 
worsened abdominal pain that lasted for >24 hours with elevat-
ed serum amylase and/or lipase levels that were >3-fold above 
the upper normal limits.17 Diagnosis of clinical cholangitis was 
based on the 2013 Tokyo guidelines that were proposed for the 
diagnosis of acute cholangitis. According to these criteria, chol-
angitis should be suspected if a patient has fever and/or shak-
ing chills, or laboratory evidence of an inflammatory response 
(abnormal white blood cell counts, increased serum C-reactive 
protein levels, or other changes that are suggestive of inflam-
mation) with jaundice or abnormal serum liver biochemistry 
(elevated ALP, AST, ALT, or γ-glutamyl transpeptidase levels).16 
Procedure-related complications, including post-ERCP pancre-
atitis (PEP), bleeding, and perforation, were graded according 
to the consensus criteria as mild (2 to 3 days of hospitalization), 
moderate (4 to 10 days of hospitalization), or severe (>10 days 
of hospitalization). PEP was diagnosed based on the presence of 
typical abdominal pain that was associated with elevated serum 
amylase levels that were >3-fold above the upper normal limit 
at 24 hours after the procedure. Bleeding was defined as clinical 
evidence of hemorrhage, such as melena or hematemesis, with a 
>2 g/dL decrease in hemoglobin levels or the need for transfu-
sion. Perforation was assessed during the procedure by visual 
inspection, or after the procedure by plain radiography. 
4. Statistical analysis
Categorical variables were analyzed using the chi-square test 
or Fisher exact test. Continuous variables were presented as 
mean±standard deviation, and were analyzed using the Mann-
Whitney test. Multivariate logistic regression analysis was used 
to evaluate the predictors of choledocholithiasis. The sensitivity, 
specificity, positive and negative predictive values, and diag-
nostic accuracy were all calculated using the 95% confidence 
interval (CI). A p-value of <0.05 was chosen as the significance 
threshold for all tests, given the Bonferroni correction that was 
conducted among the study cohort. All statistical analyses were 
performed using SPSS software version 18.0 (SPSS Inc., Chi-
cago, IL, USA).
RESULTS
A search of our database identified 200 patients with nega-
tive CT findings and an intermediate or high clinical probability 
of having CBD stones. Among these 200 patients, EUS revealed 
CBD stones in 165 patients (82.5%), and 161 patients (80.5%) 
were confirmed to have CBD stones via ERCP (Fig. 2). Eight 
patients (4.9%) were ultimately found not to have CBD stones 
using ERCP, despite positive EUS findings. In contrast, four pa-
tients (11.4%) with negative EUS findings and suspicious clini-
cal symptoms were confirmed to have CBD stones using ERCP. 
The choledocholithiasis detection rate in patients categorized 
with high and intermediate probability of choledocholithiasis 
according to ASGE guidelines is shown in Figs 3 and 4. Sixty 
patients (83.3%) with high probability had CBD stones among 
Fig. 2. Study flow chart.
CBD, common bile duct; CT, com-
puted tomography; EUS, endoscopic 
ultrasonography; ERCP, endoscopic 
retrograde cholangiopancreatogra-
phy.
157 CBD stone (+)
on ERCP
8 CBD stone ( )
on ERCP
4 CBD stone (+)
on ERCP
31 CBD stone ( )
on ERCP
200 Suspected CBD stones with high and intermediate
probability with a negative CT scan
165 CBD stone (+)
on EUS
35 CBD stone ( )
on EUS
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72 patients. EUS revealed choledocholithiasis in 59 patients 
(98.3%) (Fig. 3). One hundred one patients (78.9%) with inter-
mediate probability had CBD stones among 128 patients. EUS 
revealed choledocholithiasis in 98 patients (97%) (Fig. 4). 
The baseline characteristics of the patients are shown in Table 
1. The presence of cholangitis, CBD stones detected on EUS, 
and CBD diameter measured by EUS were significantly differ-
ent between the choledocholithiasis and noncholedocholithiasis 
groups (p<0.001, p<0.001, and p=0.029, respectively). The diag-
nostic accuracy of EUS for choledocholithiasis was 94.0% (95% 
CI, 89.4% to 97.1%) with sensitivity of 97.5% (95% CI, 93.4% to 
99.2%), specificity of 79.5% (95% CI, 63.1% to 90.1%), positive 
predictive value of 95.2% (95% CI, 90.3% to 97.7%), and nega-
tive predictive value of 88.6% (95% CI, 72.3% to 96.3%). The 
false-positive rate for an EUS diagnosis of choledocholithiasis 
was 4.8% (8/165; 95% CI, 2.3% to 9.7%) and the false-negative 
rate was 11.4% (4/35; 95% CI, 3.7% to 27.7%).
There were 24 cases (12.0%) of ERCP-related complications, 
including 14 cases (7.0%) of mild PEP, nine cases (4.5%) of mi-
nor bleeding, and one case (0.5%) of infundibulotomy-related 
perforation (Table 2). In addition, six cases (15.4%) of complica-
tions occurred in the noncholedocholithiasis group during the 
ERCP. All patients who developed complications recovered un-
eventfully, and no procedure-related mortalities occurred. 
We performed multivariate analysis to identify the indepen-
dent predictors of the presence of choledocholithiasis, using 
the factors that significantly differed between the choledocho-
lithiasis and noncholedocholithiasis groups and factors that are 
generally useful for the prediction of choledocholithiasis. The 
multivariate analysis revealed that the independent predictors 
of choledocholithiasis were the presence of CBD stones during 
EUS (odds ratio [OR], 284.51; 95% CI, 50.44 to 1,604.67), age of 
>55 years (OR, 8.46; 95% CI, 1.65 to 43.29), and a clinical diag-
nosis of cholangitis (OR, 5.84; 95% CI, 1.23 to 27.75) (Table 3). 
However, CBD dilation, liver function abnormalities, and ASGE 
probability were not significant predictors of choledocholithia-
sis.
DISCUSSION
Although CT is not the imaging technique of choice for pa-
tients with clinically suspected choledocholithiasis and is not 
mentioned in the ASGE guidelines, it is commonly used for the 
differential diagnosis of acute abdomen and for the detection of 
bile duct stones, especially in the emergency room.1,2 Interest-
ingly, helical CT scans have a reported sensitivity of 65% to 
88% and a specificity of 73% to 97% for choledocholithiasis.1,2,18 
However, the ability to detect bile duct stones by CT depends 
Fig. 3. Suspected common bile duct 
(CBD) stones with a negative com-
puted tomography scan. Patients 
with a high probability of choledo-
cholithiasis; 60 of 72 patients (83.3%) 
had CBD stones, and endoscopic ul-
trasonography (EUS) indicated cho-
ledocholithiasis in 59 of 60 patients 
(98.3%). 
59 CBD stone (+)
on ERCP
2 CBD stone ( )
on ERCP
1 CBD stone (+)
on ERCP
10 CBD stone ( )
on ERCP
72 Suspected CBD a stones with a high probability
with a negative CT scan
61 CBD stone (+)
on EUS
11 CBD stone ( )
on EUS
Fig. 4. Suspected common bile duct 
(CBD) stones with a negative com-
puted tomography scan. Patients 
with an intermediate probability; 
101 of 128 patients (78.9%) had 
CBD stones, and endoscopic ultra-
sonography (EUS) indicated choled-
ocholithiasis in 98 of 101 patients 
(97%). 
98 CBD stone (+)
on ERCP
6 CBD stone ( )
on ERCP
3 CBD stone (+)
on ERCP
21 CBD stone ( )
on ERCP
128 Suspected CBD stones with an intermediate probability
with a negative CT scan
104 CBD stone (+)
on EUS
24 CBD stone ( )
on EUS
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on a number of stone-related factors (size, shape, position, and 
density), bile duct diameter (dilated vs nondilated), CT technol-
ogy (conventional vs helical), CT technique (slice thickness, 
reconstruction interval, pitch, kVp, and administration of con-
trast material), patient selection, and interpreter variability.2,18 
Among these factors, the small size of bile duct stones and iso-
attenuation can make them more difficult to identify,2,6 and 
cholesterol stones are iso- or slightly hypo-attenuated (relative 
to bile), which makes them especially difficult to detect.2,18 In 
this study, 92 patients (57.1%) had a cholesterol stone, and 79 
(49.1%) had a stone with a diameter of <4 mm. All patients in 
this study underwent ultrasonography to measure bile duct di-
ameter, as mentioned in ASGE guidelines. However, a limitation 
of ultrasonography to evaluate full extrahepatic bile duct is that 
it could easily be disturbed by stomach gas or an obese abdo-
men. 
ERCP is highly accurate for diagnosing bile duct stones, even 
if the stones are not detected via CT, and it has been the gold 
standard for preoperative visualization of the bile duct for many 
years.1,9,19,20 However, the nonselective use of ERCP in patients 
with suspected choledocholithiasis only detects CBD stones in 
<50% of cases, and >50% of patients undergo an unnecessary 
invasive procedure, with its associated risk of morbidity and 
mortality.2,6,8,9 
Table 1. Baseline Characteristics of the Enrolled Patients
Characteristic
All
(n=200)
ERCP stone (+)
(n=161)
ERCP stone (–)
(n=39)
p-value
Age, yr 58.01±17.78 58.65±18.17 55.33±15.98 0.297
Age >55 yr 115 (57.5) 96 (59.6) 19 (48.7) 0.146
Sex, male/female 94/106 74/87 20/19 0.550
Symptoms at presentation
    Biliary pain 186 (93) 149 (92.5) 37 (94.9) 0.610
    Fever 71 (35.5) 61 (37.9) 10 (25.6) 0.152
    Jaundice 76 (38.0) 57 (35.4) 19 (48.7) 0.124
    Clinical pancreatitis 60 (30.0) 48 (29.8) 12 (30.8) 0.907
    Clinical cholangitis 109 (54.5) 98 (60.9) 11 (28.2) <0.001*
Chemistry at presentation
    Total bilirubin, mg/dL 2.54±2.11 2.61±2.18 2.26±1.77 0.194
    ALP, U/L 157±129 162±140 137±62 0.274
    γGT, U/L 407±379 414±388 379±342 0.428
    AST, IU 246±306 252±313 220±280 0.516
    ALT, IU 234±250 229±235 253±306 0.377
    Total bilirubin >4 mg/dL 158 (79.0) 125 (77.6) 33 (84.6) 0.233
    LFT >2 ULN 151 (75.5) 122 (75.8) 29 (74.4) 0.500
EUS findings
    Gallstone 122 (61.0) 97 (60.2) 25 (64.1) 0.636
    CBD stone 165 (82.5) 157 (97.5) 8 (20.5) <0.001*
    CBD dilation, >6 mm 133 (66.5) 109 (67.7) 24 (61.5) 0.464
    CBD diameter, mm 4.57±2.07 4.65±2.07 3.01±1.52 0.029*
Data are presented as the number (%) or mean±SD.
ERCP, endoscopic retrograde cholangiopancreatography; ALP, alkaline phosphatase; γGT, γ-glutamyl transferase; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; LFT, liver function test; ULN, upper limit of normal; EUS, endoscopic ultrasonography; CBD, common bile duct.
*p<0.05.
Table 2. Adverse Events of Endoscopic Retrograde Cholangiopan-
creatography
 Adverse event
ERCP stone (+)
(n=161)
ERCP stone (–)
(n=39)
Total
(n=200)
Pancreatitis* 9 (5.6) 5 (12.8) 14 (7)
Bleeding† 8 (5.0) 1 (2.6) 9 (4.5)
Perforation‡ 1 (0.6) 0 1 (0.5)
Hyperamylasemia§ 12 (7.5) 4 (10.3) 16 (8.0)
Total 30 (18.6) 10 (25.6) 40 (20)
Data are presented as the number (%). 
ERCP, endoscopic retrograde cholangiopancreatography.
*All cases were mild post-ERCP pancreatitis; †All cases were minor 
bleeding; ‡Perforation occurred during infundibulotomy; §Post-ERCP 
hyperamylasemia is defined as a 3-fold or greater increase in the se-
rum amylase level 24 hours after ERCP.
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In the last decade, many studies have demonstrated that EUS 
is as accurate as ERCP for detecting CBD stones, and that it has 
lower mortality and morbidity rates. Furthermore, diagnostic 
EUS is rarely associated with complications, compared to com-
plication rates of 5% to 6% and mortality rates of 0.07% to 
0.1% after diagnostic ERCP.3,6,21-25 In the present study, we did 
not observe any complications that were associated with EUS, 
although ERCP was associated with 24 cases (12%) of complica-
tions (excluding hyperamylasemia). Although a simple com-
parison of the complication frequencies for EUS and ERCP did 
not reveal a significant difference, six patients (15.4%) in the 
noncholedocholithiasis group experienced ERCP-related compli-
cations, such as PEP and bleeding. 
In previous studies of EUS for detecting CBD stones, all sub-
jects were usually cholangitis patients. Moreover, there is a lack 
of research regarding the necessity of immediate ERCP in pa-
tients with an intermediate or high probability of having a CBD 
stone (based on the ASGE criteria) and negative imaging find-
ings. Therefore, we focused on this group when evaluating EUS 
as the initial approach to CBD stone identification. 
EUS results are not influenced by bile duct diameter and 
stone size.5,20,26 In contrast, cholangiography often fails to detect 
CBD stones that have a diameter of <4 mm, especially in the 
dilated CBD. Therefore, because small stones may be mobile and 
move toward the intrahepatic bile ducts, the operator might fail 
to detect the stone. In addition, jet injection of contrast media 
into the CBD or overfilling of the bile ducts may decrease the 
resolution of the cholangiogram for stone detection.6
Previous studies have suggested that EUS should be used 
before ERCP in patients with an intermediate probability of 
choledocholithiasis.1,6,7,27,28 However, the management algo-
rithm for choledocholithiasis (based on the ASGE probability 
of choledocholithiasis) has several limitations. For example, the 
criteria for determining the risk of having choledocholithiasis 
are not well defined, and Buscarini et al.29 have reported that 
choledocholithiasis was present in <50% of patients who were 
classified as being at intermediate risk of having biliary obstruc-
tion (based on their clinical, biochemical, and sonographic find-
ings). In addition, liver function tests (including total bilirubin) 
are commonly used for risk stratification, although they may be 
affected by other diseases (e.g., systemic sepsis or chronic liver 
disease).9 Furthermore, according to the ASGE guidelines, a total 
bilirubin of >4 mg/dL is a very strong predictor of choledo-
cholithiasis, and direct ERCP is recommended.4 However, our 
results indicated that an elevated total bilirubin level was not a 
significant predictor of choledocholithiasis in our multivariate 
analysis. Furthermore, CBD dilation, clinical gallstone pancre-
atitis, and ASGE probability did not significantly differ between 
our study groups. Moreover, among the ASGE factors that are 
very strong or strong-to-moderate predictors, only the presence 
of clinical cholangitis and age of >55 years were strong predic-
tors of choledocholithiasis in the present study; the presence of 
CBD stones during EUS was also a strong predictor. In the pres-
ent study, the ASGE criteria provided a diagnostic rate for CBD 
stones of 83.0% in the high probability group and 78.9% in the 
intermediate group. Therefore, these criteria provided a less ac-
curate diagnosis, compared to the use of EUS. Although ERCP 
was recommended for patients in the high probability group, 
our data showed that 12 patients (16.7%) among 72 patients 
had no choledocholithiasis according to ERCP whereas EUS 
revealed that 10 (83.3%) out of 12 patients. Furthermore, if cho-
ledocholithiasis was detected on EUS, the operator could usually 
perform ERCP immediately. Thus, we suggest a revision of the 
ASGE criteria to recommend that EUS should be used to select 
patients for therapeutic ERCP and to avoid diagnostic ERCP in 
patients with intermediate or high probability of CBD stone with 
negative CT findings. 
On the other hand, because “CBD stone(+) on EUS” may af-
fect the results of multivariate analysis, we also performed the 
multivariate analysis after excluding the EUS findings. Only 
cholangitis showed a significant predictor for predicting the 
presence of choledocholithiasis (p=0.01) and age more than 55 
was not a predictor (p=0.475). However, because the p-value of 
ASGE criterion for high versus intermediate probability was 0.06, 
the ASGE criterion should not be overlooked.
There are several limitations that warrant careful interpreta-
tion of our findings. First, this was a retrospective analysis, 
which has inherent design-related limitations such as minor 
Table 3. Results of the Multivariate Analysis of the Predictors of Choledocholithiasis
Variable OR (95% CI)  p-value
Age >55 yr 8.46 (1.65–43.29) 0.010*
Clinical cholangitis 5.84 (1.23–27.75) 0.026*
CBD stone (+) on EUS  284.51 (50.44–1604.67) <0.001*
CBD diameter >6 mm on EUS 3.02 (0.74–12.34) 0.125
LFT >2 ULN 1.28 (0.25–6.46) 0.768
ASGE (high vs intermediate probability) 1.85 (0.39–8.75) 0.437
OR, odds ratio; CI, confidence interval; CBD, common bile duct; EUS, endoscopic ultrasonography; LFT, liver function test; ULN, upper limit of 
normal.
*p<0.05.
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selection bias. Second, the specificity of EUS for choledocholi-
thiasis was lower than the specificity that was reported in previ-
ous studies. Third, although EUS can clearly identify the distal 
CBD, it can fail to identify the far distal CBD, ampulla of Vater, 
and perihilar bile duct. Nevertheless, we considered that stones 
in these areas might not be identified by EUS, and so we paid 
careful attention to these areas. Fourth, ERCP as a confirmatory 
criterion standard might miss small stones. In this study, ERCP 
failed to confirm the presence of CBD stones in eight patients 
with positive EUS findings. This discrepancy may be related to 
this limitation or spontaneous stone passage. 
In the present study, we evaluated the usefulness of EUS in 
patients with intermediate or high probability of CBD stones 
and negative CT findings. Given the limited sensitivity of CT, 
the risks of ERCP-related complications, and the high diagnostic 
accuracy and safety of EUS, we propose that EUS may be a suit-
able method in these groups when determining whether patients 
should undergo more invasive ERCP procedures. 
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